The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS.
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
07
11
2021
accepted:
11
01
2022
pubmed:
23
3
2022
medline:
29
4
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
Autoinflammatory type I interferonopathies, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI), and Aicardi-Goutières syndrome (AGS) are rare and clinically complex immunodysregulatory diseases. With emerging knowledge of genetic causes and targeted treatments, a Task Force was charged with the development of "points to consider" to improve diagnosis, treatment, and long-term monitoring of patients with these rare diseases. Members of a Task Force consisting of rheumatologists, neurologists, an immunologist, geneticists, patient advocates, and an allied health care professional formulated research questions for a systematic literature review. Then, based on literature, Delphi questionnaires, and consensus methodology, "points to consider" to guide patient management were developed. The Task Force devised consensus and evidence-based guidance of 4 overarching principles and 17 points to consider regarding the diagnosis, treatment, and long-term monitoring of patients with the autoinflammatory interferonopathies, CANDLE/PRAAS, SAVI, and AGS. These points to consider represent state-of-the-art knowledge to guide diagnostic evaluation, treatment, and management of patients with CANDLE/PRAAS, SAVI, and AGS and aim to standardize and improve care, quality of life, and disease outcomes.
Types de publication
Journal Article
Systematic Review
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
735-751Informations de copyright
© 2022 American College of Rheumatology. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Références
Sanchez GA, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 2018;128:3041-52.
Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q, et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest 2015;125:4196-211.
Crow YJ, Manel N. Aicardi-Goutières syndrome and the type I interferonopathies [review]. Nat Rev Immunol 2015;15:429-40.
Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian interferonopathies: comparison of CANDLE, SAVI with AGS, monogenic lupus. J Mol Med 2016;94:1111-27.
Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T, et al. Proteasome assembly defect due to a proteasome subunit β type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A 2011;108:14914-9.
Piccoli C, Bronner N, Gavazzi F, Dubbs H, De Simone M, De Giorgis V, et al. Late-onset Aicardi-Goutières syndrome: a characterization of presenting clinical features. Pediatr Neurol 2021;115:1-6.
Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Sanchez GA, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014;371:507-18.
Frémond ML, Hadchouel A, Berteloot L, Melki I, Bresson V, Barnabei L, et al. Overview of STING-associated vasculopathy with onset in infancy (SAVI) among 21 patients. J Allergy Clin Immunol Pract 2021;9:e11:803-18.
Garg A, Hernandez MD, Sousa AB, Subramanyam L, de Villareal LM, dos Santos HG, et al. An autosomal recessive syndrome of joint contractures, muscular atrophy, microcytic anemia, and panniculitis-associated lipodystrophy. J Clin Endocrinol Metab 2010;95:E58-63.
Li J, An S, Du Z. Familial interstitial lung disease caused by mutation of the STING1 gene. Front Pediatr 2020;8:543.
Stellitano LA, Winstone AM, van der Knaap MS, Verity CM. Leukodystrophies and genetic leukoencephalopathies in childhood: a national epidemiological study. Dev Med Child Neurol 2016;58:680-9.
De Jesus AA, Hou Y, Brooks S, Malle L, Biancotto A, Huang Y, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest 2020;130:1669-82.
Kim H, de Jesus AA, Brooks SR, Liu Y, Huang Y, VanTries R, et al. Development of a validated interferon score using NanoString technology. J Interferon Cytokine Res 2018;38:171-85.
Van der Heijde D, Aletaha D, Carmona L, Edwards CJ, Kvien TK, Kouloumas M, et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
Niederberger M, Spranger J. Delphi technique in health sciences: a Map. Front Public Health 2020;8:457.
OCEBM Levels of Evidence Working Group. Oxford Centre for Evidence-Based Medicine: levels of evidence (March 2009). URL: https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/.
Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 1981.
Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, et al. Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 2012;64:895-907.
Crow YJ, Jackson AP, Roberts E, van Beusekom E, Barth P, Corry P, et al. Aicardi-Goutières syndrome displays genetic heterogeneity with one locus (AGS1) on chromosome 3p21. Am J Hum Genet 2000;67:213-21.
Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford) 2017;56:1662-75.
Crow YJ, Shetty J, Livingston JH. Treatments in Aicardi-Goutières syndrome. Dev Med Child Neurol 2020;62:42-7.
Adang L, Gavazzi F, De Simone M, Fazi E, Galli J, Koh J, et al. Developmental outcomes of Aicardi Goutières syndrome. J Child Neurol 2020;35:7-16.
Adang LA, Gavazzi F, Jawad AF, Cusack SV, Kopin K, Peer K, et al. Development of a neurologic severity scale for Aicardi Goutières syndrome. Mol Genet Metab 2020;130:153-60.
Torrelo A. CANDLE syndrome as a paradigm of proteasome-related autoinflammation. Front Immunol 2017;8:927.
Lanzi G, Fazzi E, D'Arrigo S, Orcesi S, Maraucci I, Bertini E, et al. The natural history of Aicardi-Goutières syndrome: follow-up of 11 Italian patients. Neurology 2005;64:1621-4.
Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther 2018;104:364-73.
Wang BX, Grover SA, Kannu P, Loon G, Laxer RM, Yeh EA, et al. Interferon-stimulated gene expression as a preferred biomarker for disease activity in Aicardi-Goutières syndrome. J Interferon Cytokine Res 2017;37:147-52.
Rice GI, Duany YD, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014;46:503-9.
Livingston JH, Lin JP, Dale RC, Gill D, Brogan P, Munnich A, et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet 2014;51:76-82.
Armangue T, Orsini JJ, Takanohashi A, Gavazzi F, Conant A, Ulrick N, et al. Neonatal detection of Aicardi Goutières syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots. Mol Genet Metab 2017;122:134-9.
Garau J, Cavallera V, Valente M, Tonduti D, Sproviero D, Zucca S, et al. Molecular genetics and interferon signature in the Italian Aicardi Goutières syndrome cohort: report of 12 new cases and literature review. J Clin Med 2019;8:750.
Omoyinmi E, Standing A, Keylock A, Price-Kuehne F, Gomes SM, Rowcxenio D, et al. Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis. PLoS One 2017;12:e0181874.
Al Mutairi F, Alfadhel M, Nashabat M, El-Hattab AW, Ben-Omran T, Hertecant J, et al. Phenotypic and molecular spectrum of Aicardi-Goutières syndrome: a study of 24 patients. Pediatr Neurol 2018;78:35-40.
Crow YJ, Chase DS, Schmidt JL, Szynkiewicz M, Forte GM, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A 2015;167A:296-312.
De Jesus AA, Brehm A, VanTries R, Pillet P, Parentelli AS, Sanchez GA, et al. Novel proteasome assembly chaperone mutations in PSMG2/PAC2 cause the autoinflammatory interferonopathy CANDLE/PRAAS4. J Allergy Clin Immunol 2019;143:1939-43.
Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I, Nishizaea M, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest 2011;121:4150-60.
Agarwal AK, Xing C, DeMartino GN, Mizrachi D, Hernandez MD, Sousa AB, et al. PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 2010;87:866-72.
Sarrabay G, Méchin D, Salhi A, Boursier G, Rittore C, Crow Y, et al. PSMB10, the last immunoproteasome gene missing for PRAAS. J Allergy Clin Immunol 2020;145:1015-7.
Ayaki T, Murata K, Kanazawa N, Uruha A, Ohmura K, Sugie K, et al. Myositis with sarcoplasmic inclusions in Nakajo-Nishimura syndrome: a genetic inflammatory myopathy. Neuropathol Appl Neurobiol 2020;46:579-87.
Sönmez HE, Karaaslan C, de Jesus AA, Batu ED, Anlar B, Sözeri B, et al. A clinical score to guide in decision making for monogenic type I IFNopathies. Pediatr Res 2020;87:745-52.
Vanderver A, Prust M, Kadom N, Demarest S, Crow YJ, Helman G, et al. Early-onset Aicardi-Goutières syndrome: magnetic resonance imaging (MRI) pattern recognition. J Child Neurol 2015;30:1343-8.
Tonduti D, Izzo G, D'Arrigo S, Riva D, Moroni I, Zorzi G, et al. Spontaneous MRI improvement and absence of cerebral calcification in Aicardi-Goutières syndrome: diagnostic and disease-monitoring implications. Mol Genet Metab 2019;126:489-94.
Clarke SL, Robertson L, Rice GI, Seabra L, Hilliard TN, Crow YJ, et al. Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype. Pediatr Rheumatol Online J 2020;18:37.
König N, Fiehn C, Wolf C, Schuster M, Costa EC, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis 2017;76:468-72.
Jain A, Misra DP, Sharma A, Wakhlu A, Agarwal V, Negi VS. Vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes [review]. Rheumatol Int 2018;38:13-24.
Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest 2014;124:5516-20.
Lin B, Berard R, Al Rasheed A, Aladba B, Kranzusch PJ, Henderlight M, et al. A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI). J Allergy Clin Immunol 2020;146:1204-8.
Uggenti C, Lepelley A, Depp M, Badrock AP, Rodero MP, El-Daher MT, et al. cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nat Genet 2020;52:1364-72.
Xin B, Jones S, Puffenberger EG, Hinze C, Bright A, Tan H, et al. Homozygous mutation in SAMHD1 gene causes cerebral vasculopathy and early onset stroke. Proc Natl Acad Sci U S A 2011;108:5372-7.
Ramantani G, Kohlhase J, Hertzberg C, Innes AM, Engel K, Hunger S, et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome. Arthritis Rheum 2010;62:1469-77.
Torrelo A, Patel S, Colmenero I, Gurbindo D, Lendínez F, Hernández A, et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol 2010;62:489-95.
Medinilla EE, García MV, Ramírez MD, Medina RC, Antón JL. Aicardi-Goutières syndrome: phenotypic and genetic spectrum in a series of three cases. An Pediatr 2019;90:312-4. In Spanish.
Videira G, Malaquias MJ, Laranjinha I, Martins R, Taipa R, Magalhães M. Diagnosis of Aicardi-Goutières syndrome in adults: a case series. Mov Disord Clin Pract 2020;7:303-7.
Abe J, Nakamura K, Nishikomori R, Kato M, Mitsuiki N, Izawa K, et al. A nationwide survey of Aicardi-Goutières syndrome patients identifies a strong association between dominant TREX1 mutations and chilblain lesions: Japanese cohort study. Rheumatology (Oxford) 2014;53:448-58.
Yarbrough K, Danko C, Krol A, Zonana J, Leitenberger S. The importance of chilblains as a diagnostic clue for mild Aicardi-Goutières syndrome. Am J Med Genet A 2016;170:3308-12.
Frémond ML, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol 2016;138:1752-5.
Keskitalo S, Haapaniemi E, Einarsdottir E, Rajamäki K, Heikkilä H, Ilander M, et al. Novel TMEM173 mutation and the role of disease modifying alleles. Front Immunol 2019;10:2770.
Melki I, Rose Y, Uggenti C, Van Eyck L, Frémond ML, Kitabayashi N, et al. Disease-associated mutations identify a novel region in human sting necessary for the control of type I interferon signaling. J Allergy Clin Immunol 2017;140:543-52.
Volpi S, Insalaco A, Caorsi R, Santori E, Messia V, Sacco O, et al. Efficacy and adverse events during Janus kinase inhibitor treatment of SAVI syndrome. J Clin Immunol 2019;39:476-85.
Tang X, Xu H, Zhou C, Peng Y, Liu H, Liu J et al. STING-associated vasculopathy with onset in infancy in three children with new clinical aspect and unsatisfactory therapeutic responses to tofacitinib. J Clin Immunol 2020;40:114-22.
Picard C, Thouvenin G, Kannengiesser C, Dubus JC, Jeremiah N, Rieux-Laucat F, et al. Severe pulmonary fibrosis as the first manifestation of Interferonopathy (TMEM173 mutation). Chest 2016;150:e65-71.
Cattalini M, Galli J, Andreoli L, Olivieri I, Ariaudo G, Fredi M, et al. Exploring autoimmunity in a cohort of children with genetically confirmed Aicardi-Goutières syndrome. J Clin Immunol 2016;36:693-9.
Kolivras A, Aeby A, Crow YJ, Rice GI, Sass U, André J, et al. Cutaneous histopathological findings of Aicardi-Goutières syndrome, overlap with chilblain lupus. J Cutan Pathol 2008;35:774-8.
Crow YJ, Zaki MS, Abdel-Hamid MS, Abdel-Salam G, Boespflug-Tanguy O, Cordiero NJ, et al. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. Neuropediatrics 2014;45:386-91.
Izzotti A, Pulliero A, Orcesi S, Cartiglia C, Longobardi MG, Capra V, et al. Interferon-related transcriptome alterations in the cerebrospinal fluid cells of Aicardi-Goutières patients. Brain Pathol 2009;19:650-60.
La Piana R, Uggetti C, Roncarolo F, Vanderver A, Olivieri I, Tonduti D, et al. Neuroradiologic patterns and novel imaging findings in Aicardi-Goutières syndrome. Neurology 2016;86:28-35.
Salerno S, Granata C, Trapenese M, Cannata V, Curione D, Espagnet MC, et al. Is MRI imaging in pediatric age totally safe? A critical reprisal [review]. Radiol Med 2018;123:695-702.
Livingston JH, Stivaros S, van der Knaap MS, Crow YH. Recognizable phenotypes associated with intracranial calcification. Dev Med Child Neurol 2013;55:46-57.
Abdel-Salam GM, Zaki MS, Lebon P, Meguid NA. Aicardi-Goutières syndrome: clinical and neuroradiological findings of 10 new cases. Acta Paediatr 2004;93:929-36.
Uggetti C, La Piana R, Orcesi S, Egitto MG, Crow YJ, Fazzi E. Aicardi-Goutieres syndrome: neuroradiologic findings and follow-up. AJNR Am J Neuroradiol 2009;30:1971-6.
Uyur-Yalcin E, Maras-Genc H, Kara B. Clinical and neuroradiologic variability of Aicardi-Goutieres syndrome: two siblings with RNASEH2C mutation and a boy with TREX1 mutation. Turk J Pediatr 2015;57:504-8.
Goutières F, Aicardi J, Barth PG, Lebon P. Aicardi-Goutières syndrome: an update and results of interferon-α studies. Ann Neurol 1998;44:900-7.
Lanzi G, Fazzi E, D'Arrigo S. Aicardi-Goutières syndrome: a description of 21 new cases and a comparison with the literature. Eur J Paediatr Neurol 2002;6 Suppl:A9-22.
Ramesh V, Bernardi B, Stafa A, Garone C, Franzoni E, Abinum M, et al. Intracerebral large artery disease in Aicardi-Goutières syndrome implicates SAMHD1 in vascular homeostasis. Dev Med Child Neurol 2010;52:725-32.
Rossler L, Ludwig-Seibold C, Thiels C, Schaper J. Aicardi-Goutières syndrome with emphasis on sonographic features in infancy. Pediatr Radiol 2012;42:932-40.
Crow YJ, Massey RF, Innes JR, Pairaudeau PW, Hills CA, Woods CG, et al. Congenital glaucoma and brain stem atrophy as features of Aicardi-Goutières syndrome. Am J Med Genet A 2004;129A:303-7.
Thiele H, du Moulin M, Barczyk K, George C, Schwindt W, Nürnberg G, et al. Cerebral arterial stenoses and stroke: novel features of Aicardi-Goutières syndrome caused by the Arg164X mutation in SAMHD1 are associated with altered cytokine expression. Hum Mutat 2010;31:E1836-50.
Adang LA, Frank DB, Gilani A, Takanohashi A, Ulrick N, Collins A, et al. Aicardi Gières syndrome is associated with pulmonary hypertension. Mol Genet Metab 2018;125:351-8.
Samanta D, Ramakrishnaiah R, Crary SE, Sukumaran S, Burrow TA. Multiple autoimmune disorders in Aicardi-Goutières syndrome. Pediatr Neurol 2019;96:37-9.
Cross Z, Kriegermeier A, McMann J, Rand E, Takanohashi A, Ulrick N, et al. Autoimmune hepatitis in Aicardi-Goutieres syndrome. Neurology 2019;92 Suppl 15:4.6-045.
Ishikawa T, Tamura E, Kasahara M, Uchida H, Higuchi M, Kobayashi H, et al. Severe liver disorder following liver transplantation in STING-associated vasculopathy with onset in infancy. J Clin Immunol 2021;41:967-74.
Ford ES, Ajani UA, Mokdad AH, on behalf of the National Health and Nutrition Examination Survey. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005;28:878-81.
Rice G, Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007;81:713-25.
Abe J, Izawa K, Nishikomori R, Awaya T, Kawai T, Yasumi T, et al. Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus. Rheumatology (Oxford) 2013;52:406-8.
Hebbar M, Kanthi A, Shrikiran A, Patil S, Muranjan M, Francis F, et al. p.Arg69Trp in RNASEH2C is a founder variant in three Indian families with Aicardi-Goutières syndrome. Am J Med Genet A 2018;176:156-60.
Tumienė B, Voisin N, Preikšaitienė E, Petroška D, Grinkinienė J, Samaitienė R, et al. Inflammatory myopathy in a patient with Aicardi-Goutières syndrome. Eur J Med Genet 2017;60:154-8.
Dale RC, Gornall H, Singh-Grewal D, Alcausin M, Rice GI, Crow YJ. Familial Aicardi-Goutières syndrome due to SAMHD1 mutations is associated with chronic arthropathy and contractures. Am J Med Genet A 2010;152A:938-42.
Buers I, Rice GI, Crow YJ, Rutsch F. MDA5-associated neuroinflammation and the Singleton-Merten syndrome: two faces of the same type I Interferonopathy spectrum [review]. J Interferon Cytokine Res 2017;37:214-9.
Saldanha RG, Balka KR, Davidson S, Wainstein BK, Wong M, Macintosh R, et al. A mutation outside the dimerization domain causing atypical STING-associated vasculopathy with onset in infancy. Front Immunol 2018;9:1535.
Cooray S, Henderson R, Solebo AL, Ancliffe P, Eleftheriou D, Brogan PA. Retinal vasculopathy in STING-associated vasculitis of infancy (SAVI). Rheumatology (Oxford) 2021;60:e351-3.
Crow Y, Keshavan N, Barbet JP, Bercu G, Bondet V, Boussard C, et al. Cardiac valve involvement in ADAR-related type I interferonopathy. J Med Genet 2020;57:475-8.
Lee-Kirsch MA. The type I interferonopathies. Annu Rev Med 2017;68:297-315.
Al-Mayouf SM, AlSaleem A, AlMutairi N, AlSonbul A, Alzaid T, Alazami AM, et al. Monogenic interferonopathies: phenotypic and genotypic findings of CANDLE syndrome and its overlap with C1q deficient SLE. Int J Rheum Dis 2018;21:208-13.
Poli MC, Ebstein F, Nicholas SK, de Guzman MM, Forbes LR, Chinn IK, et al. Heterozygous truncating variants in POMP escape nonsense-mediated decay and cause a unique immune dysregulatory syndrome. Am J Hum Genet 2018;102:1126-42.
Vanderver A, Adang L, Gavazzi F, McDonald K, Helman G, Frank DB, et al. Janus kinase inhibition in the Aicardi-Goutières syndrome. N Engl J Med 2020;383:986-9.
Meesilpavikkai K, Dik WA, Schrijver B, van Helden-Meeuwsen CG, Versnel MA, van Hagen PM, et al. Efficacy of baricitinib in the treatment of chilblains associated with Aicardi-Goutières syndrome, a type I interferonopathy. Arthritis Rheumatol 2019;71:829-31.
Zimmermann N, Wolf C, Schwenke R, Lüth A, Schmidt F. Engel K, et al. Assessment of clinical response to Janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation. JAMA Dermatol 2019;155:342-6.
Patel PN, Hunt R, Pettigrew ZJ, Shirley JB, Vogel TP, de Guzman MM. Successful treatment of chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome with tofacitinib. Pediatr Dermatol 2021;38:528-9.
Rice GI, Meyzer C, Bouazza N, Hully M, Boddaert N, Semeraro M. et al. Reverse-transcriptase inhibitors in the Aicardi-Goutières syndrome. N Engl J Med 2018;379:2275-7.
Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010;77:299-311.
Smith JM, McDonald RA, Finn LS, Healey PJ, Davis CL, Limaye AP, et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004;4:2109-17.
Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289-94.
Frémond ML, Crow YJ. Sting-mediated lung inflammation and beyond. J Clin Immunol 2021;41:501-14.
Ramantani G, Maillard LG, Bast T, Husain RA, Niggeman P, Kohlhase K, et al. Epilepsy in Aicardi-Goutières syndrome. Eur J Paediatr Neurol 2014;18:30-7.
Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity [review]. Annu Rev Immunol 2005;23:307-35.
Ma M, Mazumder S, Kwak H, Adams M, Gregory M. Case report: acute thrombotic microangiopathy in a patient with STING-associated vasculopathy with onset in infancy (SAVI). J Clin Immunol 2020;40:1111-5.
Abid Q, Best Rocha A, Larsen CP, Schulert G, Marsh R, Yasin S, et al. APOL1-associated collapsing focal segmental glomerulosclerosis in a patient with stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI). Am J Kidney Dis 2020;75:287-90.
Adang L, Goldbach-Mansky R, Vanderver A. JAK inhibition in the Aicardi-Goutières syndrome. N Engl J Med 2020;383:2191-3.
Wahezi DM, Lo MS, Rubinstein TB, Ringold S. Ardoin SP, Downes KJ, et al. American College of Rheumatology guidance for the management of pediatric rheumatic disease during the COVID-19 pandemic: version 1. Arthritis Rheumatol 2020;72:1809-19.
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79:39-52.
Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3. Arthritis Rheumatol 2021;73:e60-75.